Learning Objectives: After studying this article, the participant should be able to: 1. Identify the risk factors associated with venous thromboembolism. 2. Categorize a patient's individual risk as low, moderate, high, or highest. 3. Understand the available medications and devices that prevent venous thromboembolism. 4. Have a working algorithm of the appropriate prophylaxis options for each risk group.
The term venous thromboembolism refers to a spectrum of disease that includes deep venous thrombosis and pulmonary embolism. Both deep venous thrombosis and pulmonary embolism are often clinically silent and thus difficult to diagnose, which leads to a substantial delay in treatment that results in high rates of morbidity and mortality. The purposes of this article are to help physicians determine the proper venous thromboembolism prophylaxis and to simplify the complex problem of treating venous thromboembolism. The tools provided in this article will help expedite and clarify the decision-making process. (Plast. Reconstr. Surg. 114: 43e, 2004.) The term venous thromboembolism refers to a spectrum of disease that includes deep venous thrombosis and pulmonary embolism. Pulmonary embolism, which remains the most preventable cause of hospital death, usually arises from deep venous thrombosis occurring in the deep veins of the lower extremities at or proximal to the popliteal veins. Pulmonary embolism is responsible for more than 200,000 deaths annually in the United States. The majority of patients who experience an acute event die within 30 minutes, well before any beneficial therapy can be initiated. 1 More than 50 percent of patients diagnosed with pulmonary embolism die within 1 year, and of those who survive, 1 percent develop chronic pulmonary hypertension and 5 percent die of recurrent pulmonary embolism. 2 Both deep venous thrombosis and pulmonary embolism are often clinically silent and thus difficult to diagnose, which leads to a substantial delay in treatment that results in high rates of morbidity and mortality. 3 
INCIDENCE
Venous thromboembolism is a well-documented risk of surgery. The incidence of fatal pulmonary embolism in patients who do not receive any form of prophylaxis is 0.1 to 0.8 percent in patients undergoing elective general surgery, 2 to 3 percent in patients undergoing elective hip replacement, and 4 to 7 percent in patients undergoing surgery for a fractured hip. 4 Although there is less information about the risk of venous thromboembolism in plastic surgery, one large study reported a 0.39 percent risk of deep venous thrombosis and a 0.16 percent risk of pulmonary embolism in face lift patients. On the basis of the 2001 national plastic surgery statistics, this amounts to 485 and 199 cases of deep venous thrombosis and pulmonary embolism, respectively, in face lift patients. This same study demonstrated that 83.7 percent of the face lift patients who developed venous thromboembolism had received general anesthesia, whereas only 16.3 percent of the venous thromboembolism cases occurred with local anesthesia and sedation. 5 Grazer and Goldwyn 6 reported a deep venous thrombosis incidence of 1.1 percent and pul-monary embolism incidence of 0.8 percent in abdominoplasty patients. Applying these percentages to the 2001 national plastic surgery statistics for abdominoplasty indicates 644 cases of deep venous thrombosis and 468 cases of pulmonary embolism for that year. Similarly, Hester et al. 7 found that when abdominoplasty was combined with other surgical procedures, the incidence of pulmonary embolism was significantly greater. Clearly, plastic surgery is not immune to the dangers of venous thromboembolism. On the basis of these studies and given the broad scope of plastic surgery procedures, it is imperative to understand the risks for venous thromboembolism in various operations and to use this information to help govern the use of venous thromboembolism prophylaxis in plastic surgery.
RISK FACTORS
Certain factors are known to increase the risk of venous thromboembolism. Knowledge of these specific risk factors forms the basis for risk category assignment. A thorough history and review of the patient's medications are essential for detecting and assigning risk. Factors known to increase the risk of venous thromboembolism include increased age, malignancy, history of spontaneous miscarriages, pregnancy, oral contraceptive use, previous venous thromboembolism, heart failure, obesity, paralysis, or the presence of a thrombophilic abnormality.
These genetic thrombophilic conditions include activated protein C resistance (factor V Leiden), prothrombin variant 20210A, antiphospholipid antibodies, protein C or protein S deficiency or dysfunction, antithrombin deficiency or dysfunction, hyperhomocystinemia, heparin-induced thrombocytopenia, dysfibrinogenemia, and polycythemia vera. 8 Of these conditions, factor V Leiden is the most common inhibitor deficiency state. It is present in 3 to 7 percent of the Caucasian population and involves a mutation in the gene encoding for coagulation factor V. 9 The mutated factor V, known as factor V Leiden, is resistant to inactivation by activated protein C 10 ( Fig. 1) . Unfortunately, the risk of venous thromboembolism is increased with more than one condition. Ridker et al. 11 reported that compared with the general population, there is a 10-fold increase of venous thromboembolism among men who have both the factor V Leiden condition and hyperhomocystinemia. Interestingly, the risk of venous thromboembolism among these patients was greater than the sum of the individual risks of factor V Leiden and hyperhomocystinemia combined. 11 This type of enhanced risk deserves special attention when evaluating a patient's overall risk.
RISK ASSIGNMENT
In 2001, following its sixth consensus conference, the American College of Chest Physicians published four risk categories based on age, clinical setting, and known risk factors. 8 It also pooled information from randomized trials to calculate the risk of venous thromboembolism for each risk group. surgery and a known history of venous thromboembolism, cancer, or a hypercoagulable state; hip or knee arthroplasty; hip fracture surgery; major trauma; or spinal cord injury. 8 The American College of Chest Physicians also collected information from a multitude of studies to determine the risk for calf deep venous thrombosis, proximal deep venous thrombosis, clinical pulmonary embolism, and fatal pulmonary embolism in each risk group for patients without prophylaxis. This publication is the cornerstone of current prophylactic recommendations, but its limitations are its undefined descriptions (e.g., minor surgery, major surgery) and lack of specified risk factors. Similarly, the study did not include plastic surgery patients and does not take into account the magnitude of a problem that postoperative bleeding can cause our unique patient population. Despite its limitations, it provides an accurate account of the scope of the problem and lists the effective therapies that have been proven to combat it.
RISK ASSESSMENT MODEL
There is a growing amount of clinical and genetic information that pertains to the risks of venous thromboembolism. To be effective in identifying and quantifying risk, the physician must have a reliable and comprehensive system that is relatively simple and easy to use in the clinical setting. Several models have been proposed to accomplish this task. The models of the 1970s and 1980s were based on laboratory values used in patient screening. 12 These models fell out of favor because of their complex and cumbersome construction. As more information came to light, the early models gave way to more comprehensive models. These models combine clinical risk factors with the risks of the surgical setting to establish an overall risk group, which has specific thromboprophylactic recommendations.
Most of the current risk assessment models are based on the categories of low, moderate, and high as described by Salzman and Hirsh in 1982. 13 One recent risk assessment model proposed by Caprini et al., 2 however, combines the strengths of the existing risk assessment models and presents an easy-to-use scoring system to assign a risk group. Figure 2 is based on this risk assessment model, with specific modifications pertaining to plastic surgery. The risk assessment model is broken down into three steps. The first step pertains to the "exposing" risk factors associated with the clinical setting. A score is given for the combined factors in this first step. The second step involves assessing "predisposing" risk factors associated with the patient. A score is given for the combined factors in the second step. The scores from steps 1 and 2 are combined to yield an overall score, which is then used to assign a risk group, which has specific prophylactic recommendations. 2 This allows for easy assessment with clear management options.
PROPHYLAXIS
Primary thromboprophylaxis is far and away the most useful and cost-effective strategy for reducing the risk of venous thromboembolism in surgical patients. It is accomplished by using pharmacological or physical methods or a combination of both. The most widely studied and recommended methods include aspirin, elastic compression stockings, intermittent pneumatic compression stockings, low-dose unfractionated heparin, low-molecular-weight heparin, and warfarin. It is incumbent on the physician to tailor recommendations to the individual risks of the patient.
Early Ambulation and Positioning
Early ambulation and proper positioning on the operating table are logical measures that should be applied to all patients undergoing surgery regardless of their risk. With regard to positioning, the technique is to position the patient in such a way to maximize venous flow through the legs and avoid external pressure. Maximum blood flow through the popliteal vein occurs with the knee slightly flexed at 5 degrees. 4 Placing a pillow under the knees will help accomplish this. Proper positioning and early ambulation are recommended for all risk groups, regardless of additional therapeutic measures. In the low-risk group, these methods alone are sufficient to effectively reduce the risk of venous thromboembolism.
Aspirin
The use of aspirin in the prevention of venous thromboembolism has been extensively studied. Although meta-analysis has shown that aspirin decreased the incidence of venous thromboembolism in both orthopedic and general surgery patients, this reduction was significantly less than that achieved by other agents. Both gastrointestinal bleeding and wound-related bleeding were increased in patients treated with aspirin. Thus, because of aspirin's lower efficacy and high-risk profile, it is not recommended for the prophylaxis of venous thromboembolism. 8 
Elastic Compression Stockings
Graded elastic compression stockings have been shown to reduce the incidence of deep venous thrombosis.
14 Their mechanism of action is to increase venous return by applying constant pressure to the lower extremity. Only compliance and unusual limb size limit the use of elastic compression stockings. There are no major side effects or strict contraindications associated with their use. When used in combination with low-dose unfractionated heparin, elastic compression stockings have been shown to provide better prophylaxis than either agent used alone. 15 There is also evidence that intermittent pneumatic compression stockings may have a beneficial effect when combined with elastic compression stockings. 16 The studies on the efficacy of elastic compression stockings are limited in number, however, and often exclude higher-risk patients. They are not recommended for monotherapy and need to be studied further to more clearly define their role in prophylaxis.
Intermittent Pneumatic Compression Stockings
Intermittent pneumatic compression stockings are recommended for solo prophylaxis in both the moderate-and high-risk groups and with low-molecular-weight heparin in highestrisk patients. These devices prevent venous thromboembolism by two distinct mechanisms. They reduce stasis by increasing venous return through the deep veins of the legs. Also, pneumatic compression, via a poorly understood mechanism, reduces the level of plasminogen activator-1, which in turn increases fibrinolytic activity. 17 Compared with the other options, intermittent pneumatic compression stockings have the combined advantage of being a very effective reducer of venous thromboembolism without causing an increased risk of bleeding. Their use should be initiated before the induction of anesthesia and avoided in patients with peripheral vascular disease or in those who have been immobilized for more than 72 hours. Intermittent pneumatic compression stockings with elastic compression stockings should begin before the operative procedure, especially if general anesthesia is being used. The rationale behind this is that general anesthesia is associated with higher rates of venous thromboembolism. Use of the intermittent pneumatic compression stockings should continue into the postoperative period until the patient is fully ambulatory. There is evidence that intermittent pneumatic compression stockings may have a beneficial effect when combined with elastic compression stockings. 16 
Heparin versus Low-Molecular-Weight Heparin
Both low-dose unfractionated heparin and low-molecular-weight heparin are recommended by the American College of Chest Physicians as prophylactic agents in the moderateand high-risk groups and together with intermittent pneumatic compression stockings and elastic compression stockings in the highestrisk group. Low-dose unfractionated heparin and low-molecular-weight heparin are equally effective in preventing deep venous thrombosis in general and orthopedic surgery patients. 16, 18 Despite their similarities in effectiveness, however, they have very different risk profiles.
There is controversy in the literature with regard to which of these therapies causes more bleeding. The discrepancy appears to be related to the dose of low-molecular-weight heparin. It has been reported that low-molecularweight heparin has a dose-related effect on bleeding complications. Doses higher than 3400 anti-Xa units daily are more likely to cause bleeding than the standard 5000 units of heparin administered every 8 or 12 hours. 19 Despite the increased risk with higher doses, low-molecular-weight heparin at doses less than 3400 anti-Xa units is equivalent to heparin in preventing venous thromboembolism and has a lower rate of bleeding complications. Therefore, at the proper dose (Ͻ3400 anti-Xa units), low-molecular-weight heparin is as effective as heparin and causes less of a bleeding risk, making it the better choice for venous thromboembolism prophylaxis in plastic surgery.
Another advantage of low-molecular-weight heparin is that it can be given once daily. Because it has greater bioavailability when administered by subcutaneous injection, its effect is more closely correlated with body weight. Lowmolecular-weight heparin is also associated with a significantly lower incidence of heparininduced thrombocytopenia than heparin: 0 versus 2.7 percent. 20 It is more expensive than heparin, however. On average, it is two to 10 times more expensive than heparin. 8 Optimal timing of the first dose of lowmolecular-weight heparin has been the subject of considerable debate. Several studies found that when it is given 2 hours preoperatively, there is a protective effect during surgery and in the immediate postoperative period. 21, 22 There is a slightly higher risk of bleeding with preoperative dosage versus postoperative dosage, however. 23, 24 From these results, the American College of Chest Physicians concluded that the first dose of low-molecular-weight heparin may be given either before or after surgery. The decision should be based on the risks and consequences of bleeding, and if started postoperatively, then initiation should be delayed for at least 12 hours after surgery. Re-gardless of the initiation of low-molecularweight heparin, therapy should be continued until the patient is fully ambulatory.
Warfarin
Warfarin (coumadin) is only indicated for patients in the highest-risk group. For these patients, the two most effective and beststudied agents are warfarin and low-molecularweight heparin. Intermittent pneumatic compression stockings and elastic compression stockings alone are not effective enough to be used as a monotherapy in this group. 8 In headto-head comparisons, low-molecular-weight heparin is significantly more effective than warfarin in preventing venous thromboembolism. There is a slightly increased risk of bleeding and wound hematoma with the use of lowmolecular-weight heparin in this group. 8, 25 The use of warfarin is complicated by its delayed onset of action. It also requires frequent laboratory monitoring to avoid bleeding complications. Warfarin interacts with several other medications via the P-450 pathway, making it a complicated medication to accurately dose. Given these drawbacks and the availability of other effective agents, there is little rationale for the use of warfarin in venous thromboembolism prophylaxis in plastic surgery patients. The only exception would be a specific contraindication or refusal to use lowmolecular-weight heparin.
New Medications
There are several promising new medications in the pipeline. Recombinant hirudin, a peptide derived from the saliva of leeches, was compared with enoxaparin, and the results showed an 18.4 to 25.5 percent rate of deep venous thrombosis in patients after total hip arthroplasty. Currently, only hirudin and argatroban are approved for the treatment of heparin-induced thrombocytopenia. Fondaparin is a heparin pentasaccharide analog that has been reported in one study to significantly improve the prevention of venous thromboembolism when compared with enoxaparin. Other new low-molecular-weight heparins include dalteparin (Fragmin), tinzaparin (Innohep), and danaparoid (Orgaran). These lowmolecular-weight heparins have not been extensively compared, and the limited data that do exist suggest that any observed differences stem from the variability among the different trials. 26, 27 Although these new medications are promising, they have not been as rigorously tested as low-dose unfractionated heparin, low-molecular-weight heparin (enoxaparin), and warfarin. Thus, their role in venous thromboembolism prophylaxis is still being defined.
ALGORITHM
Plastic surgery patients present a challenge with regard to venous thromboembolism pro- PLASTIC AND RECONSTRUCTIVE SURGERY, September 1, 2004 phylaxis. Although the risks of venous thromboembolism are real, there is a reluctance to use prophylaxis because of bleeding concerns. The algorithm shown in Figure 3 is a streamlined flow chart that combines the risk assessment model of Caprini et al. 2 with the recommendations of the American College of Chest Physicians. The prophylactic options have been selected on the basis of their effectiveness and risk profile as best suited for the plastic surgery patient. Figure 4 is an order form that combines the plastic surgery risk assessment model with appropriate postoperative order selections. Enoxaparin (Lovenox) is on the formulary at Georgetown University Hospital, and its respective dose was selected based on maximizing efficacy while minimizing the risk of bleeding. Regardless of the abundance of facts and literature on this topic, determining the proper venous thromboembolism prophylaxis is still a clinical decision that should be made on a patient-to-patient basis. The algorithm presented in this article is meant to simplify this complex problem. In situations in which a patient's hypercoagulable history is well documented, it is always prudent to consult a hematologist. These tools will help expedite and clarify the decision-making process.
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